Download MendeleyDiscovery of Potent and Selective 8-Fluorotriazolopyridine c-Met Inhibitors.
Peterson, E.A., Teffera, Y., Albrecht, B.K., Bauer, D., Bellon, S.F., Boezio, A., Boezio, C., Broome, M.A., Choquette, D., Copeland, K.W., Dussault, I., Lewis, R., Lin, M.H., Lohman, J., Liu, J., Potashman, M., Rex, K., Shimanovich, R., Whittington, D.A., Vaida, K.R., Harmange, J.C.(2015) J Med Chem 58: 2417-2430
- PubMed: 25699405 Search on PubMed
- DOI: https://doi.org/10.1021/jm501913a
- Primary Citation Related Structures:
4XMO, 4XYF - PubMed Abstract:
The overexpression of c-Met and/or hepatocyte growth factor (HGF), the amplification of the MET gene, and mutations in the c-Met kinase domain can activate signaling pathways that contribute to cancer progression by enabling tumor cell proliferation, survival, invasion, and metastasis. Herein, we report the discovery of 8-fluorotriazolopyridines as inhibitors of c-Met activity. Optimization of the 8-fluorotriazolopyridine scaffold through the combination of structure-based drug design, SAR studies, and metabolite identification provided potent (cellular IC50 < 10 nM), selective inhibitors of c-Met with desirable pharmacokinetic properties that demonstrate potent inhibition of HGF-mediated c-Met phosphorylation in a mouse liver pharmacodynamic model.
- Amgen Inc. , 360 Binney Street, Cambridge, Massachusetts 02142, United States.
Organizational Affiliation:
